Editorial: Biomarkers of neurodegeneration and brain function and their relationships with clinical and neuropsychological outcomes in monitoring deep brain stimulation efficacy in movement disorder patients.

Abstract

Deep brain stimulation (DBS) is a widely used therapy for a variety of movement disorders, such as Parkinson’s disease (PD), Essential Tremor (ET), and dystonia, mainly targeting the subthalamic nucleus (STN), thalamic ventral intermediate nucleus (Vim), and globus pallidus internus (Gpi). Although this treatment has been available for decades, studies on early- or long-term patient outcomes have been still limited. While DBS has evolved into an evidence-based standard treatment for movement disorders, the identification of preoperative or postoperative predicting factors in DBS candidates would be of imperative clinical value, allowing us to monitor surgical performance and improve surgical outcomes